# US 2010/0303839 A1 · Methods and compositions for treatment of cancer using oncolytic rsv activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0303839 A1
- Document ID: US20100303839A1
- Status: Published application
- Kind: A1
- Application number: 12/601,030
- Filed: 2008-05-21
- Published: 2010-12-02
- Earliest claimed: 2007-05-21
- Assignees: Board of Regents, The University of Texas System
- Inventors: Santanu Bose; Bandana Chatterjee
- Web page: https://patentgrep.com/patent/US20100303839A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 38/208: {IL-12}
- A61K 38/45: Transferases (2)
- A61K 39/12: Viral antigens
- A61K 39/155: Paramyxoviridae, e.g. parainfluenza virus
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2760/18532: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates generally to methods and compositions employing the oncolytic activity of respiratory syncytial virus (RSV) to treat cancer and other neoplastic disorders.

## Claims

### Claim 1

A method of treating a neoplasm in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), thereby treating the neoplasm in the subject.

### Claim 2

A method of treating a cancer in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), thereby treating the cancer in the subject.

### Claim 3

A method of reducing metastasis of a primary cancer in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), thereby reducing metastasis of a primary cancer in the subject.

### Claim 4

A method of reducing tumor size and/or tumor burden in a subject comprising a tumor, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), thereby reducing tumor size and/or tumor burden in the subject.

### Claim 5

A method of inducing apoptosis of a neoplastic or tumor cell in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), thereby inducing apoptosis of a neoplastic or tumor cell in the subject.

### Claim 6

A method of reducing pain caused by a tumor in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), thereby reducing pain caused by the tumor in the subject.

### Claim 7

A method of delivering a respiratory syncytial virus (RSV) to a tumor cell in a subject, comprising administering to the subject a recombinant respiratory syncytial virus (RSV) comprising a protein that specifically binds a tumor antigen on the tumor cell.

### Claim 8

A method of increasing the sensitivity of a tumor cell to radiation, comprising infecting the tumor cell with a respiratory syncytial virus (RSV), thereby increasing the sensitivity of the tumor cell to radiation.

### Claim 9

A method of increasing the sensitivity of a tumor cell to a chemotherapeutic agent, comprising infecting the tumor cell with a respiratory syncytial virus (RSV), thereby increasing the sensitivity of the tumor cell to a chemotherapeutic agent.

### Claim 10

A method of sensitizing a tumor cell to an immune response against RSV, comprising infecting the tumor cell with a respiratory syncytial virus (RSV), whereby the respiratory syncytial virus expresses respiratory syncytial virus antigen on the surface of the tumor cell, thereby sensitizing the tumor cell to an immune response against respiratory syncytial virus.

### Claim 11

A method of treating a tumor or neoplasm in a subject, comprising removing the tumor or neoplasm from the subject and administering to the subject an oncolytic amount of a respiratory syncytial virus (RSV), thereby treating a tumor or neoplasm in the subject.

### Claim 12

A method of reducing the likelihood of recurrence of a tumor or neoplasm in a subject, comprising removing the tumor or neoplasm from the subject and administering to the subject an oncolytic amount of a respiratory syncytial virus (RSV), thereby reducing the likelihood of recurrence of a tumor or neoplasm in the subject.

### Claim 13

A method of eliminating or reducing the number of neoplastic cells in an ex vivo population of neoplastic cells and normal cells, comprising contacting the population with a respiratory syncytial virus (RSV) under conditions whereby the respiratory syncytial virus can infect the cells and kill the neoplastic cells, thereby eliminating or reducing the number of neoplastic cells in the ex vivo population.

### Claim 14

A method of preparing a cellular composition or organ for transplantation into a subject, comprising contacting the cellular composition or organ with a respiratory syncytial virus (RSV) under conditions whereby the respiratory syncytial virus can infect the cells of the cellular composition and/or organ and kill neoplastic cells present in the cellular composition or organ, thereby preparing the cellular composition or organ for transplantation into the subject.

### Claim 15 (depends on 1)

The method of claim 1, wherein the respiratory syncytial virus (RSV) has a mutation in a gene selected from the group consisting of the NS1, NS2, N, P, M, SH, G, F, M2-1/M2-2, and L genes, and any combination thereof.

### Claim 16 (depends on 1)

The method of claim 1, wherein the RSV comprises one or more than one nucleotide sequence heterologous to the virus and/or to the tumor cell.

### Claim 17 (depends on 16)

The method of claim 16, wherein the heterologous nucleotide sequence encodes a protein selected from the group consisting of a cytolytic agent, cytotoxic agent, apoptotic agent, antibody (e.g., an anti-anti-RSV antibody), tumor suppressor protein, cytokine, heterologous antigen expressed on the surface of a tumor cell to elicit an immune response, interferon, anti-angiogenesis agent, CTL responsive peptide, immunostimulatory agent, and any combination thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the apoptotic agent is a selected from the group consisting of Bax, Bad, and any combination thereof.

### Claim 19 (depends on 17)

The method of claim 17, wherein the cytotoxic agent is herpes virus thymidine kinase (TK) and is optionally used in combination with ganciclovir treatment.

### Claim 20 (depends on 17)

The method of claim 17, wherein the immuno-stimulatory agent is selected from the group consisting of human monocyte chemoattractant protein-1 (MCP-1), granulocyte-macrophage colony stimulating factor (GM-CSF), TRAIL (TNF-related apoptosis inducing ligand), interleukin-12, and any combination thereof.

### Claim 21 (depends on 17)

The method of claim 17, wherein the CTL responsive peptide is HLA-B*08-restricted RSV specific CTL epitope.

### Claim 22 (depends on 17)

The method of claim 17, wherein the anti-angiogenesis agent is selected from the group consisting of angiostatin, endostatin, Timps (tissue inhibitors of matrix metalloproteinases, and any combination thereof.

### Claim 23 (depends on 17)

The method of claim 17, wherein the tumor suppressor gene is tumor suppressor p53.

### Claim 24 (depends on 1)

The method of claim 1, further comprising administering an immunosuppressive agent, a chemotherapeutic agent, an immunostimulatory agent, radiation, or any combination thereof, before, during and/or after administration of the RSV.

### Claim 25 (depends on 24)

The method of claim 24, wherein the immunosuppressive agent is selected from the group consisting Azathioprine, Anti-anti-RSV, Alefacept, Anakinra, Anti-lymphocyte globulin, Anti-thymocyte globulin, Ascomycin, Auranofin, Aurothioglucose, Azathioprine, Basiliximab, CNTO 1275, Ciclosporin (Cyclosporine), Cortisol, Cyclic steroids, Daclizumab, Disodium aurothiomalate, Etanercept, Everolimus, Gliotoxin, Gold salts, Gusperimus, Leflunomide, Mercaptopurine, Methotrexate, Mycophenolic acid, Natalizumab, Penicillamine, Pimecrolimus, Prednisone, Rapamycin, Sirolimus, Sodium aurothiomalate, Sulfasalazine, Tacrolimus, and natural anti-cancer herbal agents, and any combination thereof.

### Claim 26 (depends on 24)

The method of claim 24, wherein the chemotherapeutic agent is selected from the group consisting of Anti-estrogens, Anthracyclins, Azacitidine, Azathioprine, Bleomycin, Busulfan, Carboplatin, Capecitabine, Cisplatin, Chlorambucil, Cyclophosphamide, Cytarabine, Dacarbazine, Daunorubicin, Docetaxel, Doxifluridine, Doxorubicin, Epirubicin, Epothilone, Etoposide, 5-Fluorouracil, Gemcitabine, Hydroxyurea, Idarubicin, Imatinib, Interferons, Mechlorethamine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin C, Mitoxantrone, Oxaliplatin, Paclitaxel, Pemetrexed, Retinoic acid, Taxol, Taxotere, Tamoxifen, Teniposide, Thiotepa, Tioguanine, Valrubicin, Vinblastine, Vincristine, Vindesine, and Vinorelbine, and any combination thereof.

### Claim 27 (depends on 24)

The method of claim 24, wherein the immunostimulatory agent is selected from the group consisting of immunostimulatory cytokines, oligodeoxynucleotide (ODN), CpG, cytotoxic/apoptotic/suicides genes and proteins, immuno-stimulatory genes and proteins, and any combination thereof.

### Claim 28 (depends on 24)

The method of claim 24, wherein the radiation is gamma radiation.

### Claim 29 (depends on 7)

The method of claim 7, wherein the tumor is a solid tumor.

### Claim 30 (depends on 7)

The method of claim 7, wherein the tumor is a hematopoietic cell tumor.

### Claim 31 (depends on 7)

The method of claim 7, wherein the tumor is a primary tumor.

### Claim 32 (depends on 7)

The method of claim 7, wherein the tumor is a metastatic tumor.

### Claim 33 (depends on 7)

The method of claim 7, wherein the tumor is selected from the group consisting of a melanoma tumor, a carcinoma tumor, an epithelioma tumor, a glioma tumor, a myeloma tumor, a leukemia, a lymphoma, an adenocarcinoma, a fibrosarcoma, a melanoma, an osteosarcoma, a synovial sarcoma, a fibrosarcoma, and a neuroblastoma, and any combination thereof.

### Claim 34 (depends on 7)

The method of claim 7, wherein the tumor is located in the prostate, lung, brain, breast, kidney, liver, lung colon, intestines, lymph, muscle, bone, bone marrow, uterus, ovary, vagina, vulva, pancreas, adrenal gland, central nervous system, peripheral nervous system, cervix, bladder, endometrium, throat, esophagus, larynx, thyroid, blood, penal, testicular, thymus, skin, spinal, stomach, anal, bile duct, bowel (colon & rectum), endocrine, eye, ball bladder, and bullet (oesophagus) tissues, and any combination thereof.

### Claim 35 (depends on 7)

The method of claim 7, wherein the tumor size is in a range from about 2 cm to about 30 cm.

### Claim 36 (depends on 7)

The method of claim 7, wherein the RSV is delivered directly to the tumor either at a single site or at multiple sites.

### Claim 37 (depends on 7)

The method of claim 7, wherein the RSV is delivered to the subject systemically.

### Claim 38 (depends on 7)

The method of claim 7 wherein the RSV is delivered by a method selected from the group consisting of intravenously, intrathecally, intraperitoneally, intrarectally, intravaginally, intranasally, intraarterially, intra-tumorally, and by inhalation, and any combination thereof.

### Claim 39 (depends on 7)

The method of claim 7, wherein the RSV is administered continuously over a period of time.

### Claim 40 (depends on 7)

The method of claim 7, wherein the RSV is administered at intervals of every hour, every two hours, every three hours, every day, every other day, every three days, every week, and/or every month.

### Claim 41 (depends on 7)

The method of claim 7, wherein the dose of RSV is administered in a range from about 1×102 pfu/ml to about 1×108 pfu/ml of virus particles.

### Claim 42 (depends on 7)

The method of claim 7, wherein the subject is selected from the group consisting of humans, nonhuman primates, dogs, cats, horses, cattle, and livestock.

### Claim 43 (depends on 7)

The method of claim 7, wherein the RSV is a live purified RSV.

### Claim 44 (depends on 7)

The method of claim 7, wherein the RSV is an attenuated RSV.

### Claim 45 (depends on 7)

The method of claim 7, wherein the RSV is selected from the group consisting of bovine RSV, human RSV, and any combination thereof.

### Claim 46 (depends on 7)

The method of claim 7, wherein the RSV is a human RSV.

### Claim 47 (depends on 7)

The method of claim 7, wherein the RSV is bovine RSV.

### Claim 48 (depends on 7)

The method of claim 7, further comprising administering one or more different oncolytic viruses, before, during and/or after administration of the RSV, wherein the one or more oncolytic viruses is selected from the group consisting of either nonengineered or engineered adenovirus, reovirus (e.g., Reolysin®), herpesvirus, Newcastle disease virus, vaccinia virus, measles virus, Coxsackie virus, vesicular stomatitis virus, parvovirus, influenza virus, and Rabbit myxoma virus, and any combination thereof.

### Claim 49

A composition comprising a respiratory syncytial virus and one or more oncolytic virus selected from the group consisting of either nonengineered or engineered adenovirus, reovirus (e.g., Reolysin®), herpesvirus, Newcastle disease virus, vaccinia virus, measles virus, Coxsackie virus, vesicular stomatitis virus, parvovirus, influenza virus and any combination thereof.

### Claim 50 (depends on 49)

The composition of claim 49, further comprising an immunosuppressive agent, a chemotherapeutic agent, an immunostimulatory agent, and/or radiation in any combination and in any order.

### Claim 51 (depends on 49)

The composition of claim 49, further comprising a pharmaceutically acceptable carrier.

### Claim 52 (depends on 49)

A kit comprising the composition of claim 49 and optionally instructions for administration.

### Claim 53

A method of treating a cancer in a subject, comprising delivering a heterologous nucleotide sequence encoding an oncolytic respiratory syncytial virus protein to a tumor cell in the subject under conditions whereby the oncolytic RSV protein is produced in the tumor cell, resulting in killing of the tumor cell, thereby treating the cancer in the subject.

### Claim 54 (depends on 53)

The method of claim 53, wherein the heterologous nucleotide sequence is delivered in a viral vector selected from the group consisting of adenovirus, adeno-associated virus, lentivirus, retrovirus based vectors, and any combination thereof.

### Claim 55

A complex comprising:
a) an RSV particle, wherein the RSV particle comprises a viral genome lacking a functional RSV gene; and
b) a nanoparticle comprising nucleic acid comprising the functional RSV gene under the control of a cell-specific promoter.

### Claim 56 (depends on 55)

The complex of claim 55, wherein the RSV gene encodes RSV G protein.

### Claim 57 (depends on 55)

The complex of claim 55, wherein the cell-specific promoter is a tumor cell-specific promoter.

### Claim 58 (depends on 55)

The complex of claim 55, wherein the cell-specific promoter is a prostate cell-specific promoter.

### Claim 59 (depends on 58)

The complex of claim 58, wherein the prostate cell-specific promoter is a prostate-specific antigen promoter.

### Claim 60 (depends on 55)

A composition comprising the complex of claim 55 in a pharmaceutically acceptable carrier.

### Claim 61 (depends on 55)

A method of establishing an RSV infection in a cell, comprising delivering to the cell the complex of claim 55.

### Claim 62 (depends on 56)

A method of treating cancer in a subject, comprising delivering the complex of claim 56 to the subject, wherein the tumor cell-specific promoter is active in a tumor cell of the subject, whereby an oncolytic RSV infection is established in the tumor cell of the subject, thereby treating the cancer in the subject.

### Claim 63 (depends on 56)

A method of inducing tumor cell-specific apoptosis in a subject, comprising delivering the complex of claim 56 to the subject, wherein the tumor cell-specific promoter is active in a tumor cell of the subject, whereby an oncolytic RSV infection is established in the tumor cell of the subject, thereby inducing tumor cell-specific apoptosis in the subject.

### Claim 64

A nanoparticle comprising a nucleic acid encoding a viral protein under the direction of a cell-specific promoter.

### Claim 65 (depends on 64)

The nanoparticle of claim 64, wherein the viral protein is RSV G protein.

### Claim 66 (depends on 64)

The nanoparticle of claim 64, wherein the cell-specific promoter is a prostate cell-specific promoter.

### Claim 67 (depends on 55)

A method of making the complex of claim 55, comprising linking the RSV particle of (a) with the nanoparticle of (b).
